Company foundation. Larisa Prokopyeva, senior researcher at the Altai Federal Research and Production Center, registers Evalar company with only 12 employees.
Received the first patent for an industrial technology for processing Altai Mumijo.
The production of MCC Ankir-B tablets begins, providing the young enterprise with a huge increase in sales and access to the pharmaceutical market in Russia.
The development of its own pharmacy chain in the Altai Territory. The first pharmacies opened in Biysk.
Ńultivation of Evalar’s own plantations in Altai
Entering CIS and Baltic markets. The company's portfolio consists of over 90 brands.
Launch of Evalar’s new manufacturing facility. Production of tableted and galenic forms. Licensed manufacturing facility for producing extracts from medicinal raw materials (5 tons of dry extracts per month).
Opening of the Moscow representative office.
The production unit for galenicals is put into operation. The company’s staff includes 1000 people.
The launch of Evalar Moscow pharmacy chain.
Decision to expand the portfolio and build a new manufacturing facility.
The Company obtains the certificate on conformity of the manufacturing facilities to the international standard of quality ISO 9001: 2008.
New manufacturing facility design completion and state examination approval.
Evalar obtains the certificate of conformity with the GMP from the Ministry of Health of Australia and enters the country’s local market. Representative offices open in Paris and Sydney. The total number of company’s employees exceeds 1300 people. The portfolio of the Altai manufacturer includes more than 300 SKU. Evalar expands its production twofold and builds another plant. The investments in the project exceed $100 million. The company continues to hold the leading position in the Russian market of natural medicinal products. The pharmacy chain Evalar has about 60 pharmacies in large cities of Russia. The annual turnover of the joint-stock company is close to 10 billion rubles.
Evalar celebrates its 25th anniversary. Evalar is included in the TOP-5 of the largest domestic pharmaceutical manufacturers. The company is building a second manufacturing plant in the Altai Territory, with a productive capacity of 6 billion tablets and capsules per year.
The company receives a GMP certificate following the results of a national audit carried out by the Ministry of Industry and Trade of the Russian Federation for compliance with the Rules of Good Manufacturing Practice (Order No. 916 of the Ministry of Industry and Trade of 14.06.13).